Weaker private equity in India for 2012, portfolios turning 'a la carte'
This article was originally published in Scrip
Executive Summary
Private equity interest in the Indian pharmaceutical sector is predicted to be somewhat tepid in 2012, with valuations turning realistic and deal sizes hovering in the $20-40 million range, according to a cross-section of experts.